FDA Fully Approves Brexucabtagene Autoleucel for Mantle Cell Lymphoma
Gilead said the U.S. Food and Drug Administration granted traditional approval to brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma, converting its earlier accelerated approval to full approval and expanding the label.
The FDA granted full approval to Tecartus for adults with relapsed or refractory mantle cell lymphoma and expanded use to include patients who have not received a Bruton tyrosine kinase inhibitor after at least one prior line of therapy.
Date: April 6, 2026
Key facts
- The FDA granted traditional approval to brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma.
- The decision converts the therapy’s earlier accelerated approval into full approval.
- The label now includes patients who are BTK inhibitor-naïve after at least one prior line of therapy.
- Regulators based the decision on results from the phase 2 ZUMA-2 study, including confirmatory data from cohort 3.
Gilead announced that the U.S. Food and Drug Administration granted traditional approval to brexucabtagene autoleucel, marketed as Tecartus, an autologous CD19-directed CAR T-cell therapy, for use in adults with relapsed or refractory mantle cell lymphoma. The FDA action converts the agency’s earlier accelerated approval to full approval and expands the treatment label to include patients who have not received a Bruton tyrosine kinase inhibitor after at least one prior line of therapy.
Regulators based their decision on results from the multicenter, open-label phase 2 ZUMA-2 study, including confirmatory data from cohort 3. The study enrolled patients with relapsed or refractory mantle cell lymphoma who had received up to five prior lines of therapy. Cohorts 1 and 2, which included 82 patients in total, enrolled patients previously treated with a BTK inhibitor, while cohort 3 enrolled 86 BTK inhibitor-naïve patients. The primary endpoint was objective response rate, as assessed by an independent radiologic review committee according to Lugano 2014 criteria.
“The cohort 3 results showed high response rates, including deep remissions, in patients who were Bruton tyrosine kinase inhibitor-naïve, with a manageable safety profile consistent with prior experience,” said Michael Wang, MD, lead trial investigator and professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston.
ZUMA-2 cohort 3 data supported full FDA approval
Among patients in cohort 3, the objective response rate was 91%, including a complete remission rate of 79%. In cohort 1, the objective response rate was 87% and the complete remission rate was 62%. Median duration of response was not reached in either cohort 3 or cohort 1 at the time of analysis, with median follow-up of 23.0 months for cohort 3 and 8.6 months for cohort 1.
These results were central to the FDA’s decision to grant full approval, because cohort 3 supplied the confirmatory evidence needed to verify and describe clinical benefit beyond the earlier accelerated approval pathway. The label expansion is especially important in relapsed or refractory mantle cell lymphoma because it broadens Tecartus use to include appropriate patients earlier in the treatment sequence who have not yet received a BTK inhibitor.
Safety profile included CRS, neurologic toxicities and infections
Safety data were pooled across all 168 patients in all three cohorts of ZUMA-2. Cytokine release syndrome occurred in 93% of patients, including grade 3 or higher events in 12%. Neurologic toxicities occurred in 80% of patients, with grade 3 or higher toxicities seen in 33%. Infections of any grade were reported in 63% of patients, including grade 3 or higher infections in 33%.
In cohort 3, serious adverse reactions occurred in 65% of patients. The most common serious adverse reactions included arrhythmias, pyrexia, cytokine release syndrome, infections, musculoskeletal pain, motor dysfunction, encephalopathy, aphasia, tremor, seizure, delirium, hypoxia, hypotension, hemorrhage and thrombosis. These findings indicate that while Tecartus can deliver high response rates and deep remissions, treatment still requires specialized monitoring and management consistent with CAR T-cell therapy standards.
FDA boxed warning remains a major part of the Tecartus profile
The agency included a boxed warning for brexucabtagene autoleucel regarding potentially life-threatening cytokine release syndrome, neurologic toxicities including immune effector cell-associated neurotoxicity syndrome, and secondary hematologic malignancies. Those warnings remain an important part of the benefit-risk profile and reinforce that Tecartus should be administered in experienced treatment settings capable of identifying and managing severe adverse events.
The full approval therefore marks a meaningful regulatory milestone for Gilead and for physicians treating relapsed or refractory mantle cell lymphoma. By converting accelerated approval into traditional approval and broadening the label to include BTK inhibitor-naïve patients after at least one prior line of therapy, the FDA has strengthened Tecartus’ role in the mantle cell lymphoma treatment landscape and expanded access to an autologous CD19-directed CAR T-cell option for appropriate adult patients.
